Ottawa Hospital Research Institute

Published purpose

With the collaboration of research hospitals across Canada, OHRI established a multi-site cellular immunotherapy pipeline. In the Project, OHRI will build on their success in establishing clinical grade manufacturing for both lentivirus and cell products, and the execution of the first clinical trial using a made-in-Canada CD19 CAR T-cell therapy. The project includes building capacity in point-of-care (POC) manufacturing to support the clinical rollout of novel CAR T-cell products and other personalized cell therapy products. The project will both increase manufacturing capacity and allow for GMP process development. This increased capacity will be used to for academically motivated clinical trials to be started by late 2024. These trials will be completed over the next five years for the benefit of cancer patients from across Canada